Impact Of Tax Preference And Financial Subsidies On R&D Investment Of Biomedical Enterprises

Today's scientific and technological progress and economic development are very rapid.All major countries in the world are striving to position their national strategic policy as scientific and technological innovation.Furthermore,in the era of rapid development of electronic information,innovation occupies a very important position.Similarly,innovation plays a very important role in the rapid development of China's social economy,and R &D investment is the key factor to improve the level of innovation.Therefore,it is necessary to strengthen the R &D investment.Biomedical industry is a new industry,which has a very good development prospect,and also has a promising development potential.Although its development prospect is very good and its development potential is promising,the progress and development of this new industry is also inseparable from the support of the government,and the government has taken various practical and effective preferential policies in the development of biomedical enterprises Cheng plays an irreplaceable role.In terms of the current academic literature,there are few scholars who study the financial and tax policies of China's biomedical enterprises in detail.This paper attempts to sort out the financial and tax policies of China's biomedical enterprises and further compare their policy effects,which is of great significance in the current research.This paper is divided into five chapters.The first chapter is the introduction,including the background and significance of the topic and the existing literature review.The second chapter is the theoretical basis.Firstly,it elaborates and defines the four related concepts of biomedical industry,R &D investment of enterprises,tax preference and financial subsidy.Then,it analyzes how tax preference and financial subsidy affect enterprises through two theories-technological innovation and market failure,so that enterprises can increase R &D investment and influence enterprise innovation.The third chapter is tax preference Analysis of the current situation of Huihe financial subsidy policy,first of all,it introduces the support mode of tax preference and financial subsidy,and analyzes the specific current situation of supporting enterprise innovation;Chapter 4 is empirical analysis,using Eviews 10.0 software to carry out empirical analysis on the enterprise data of biomedical industry in 7-year listed companies.The sample of this paper selects the enterprises in CSMAR pharmaceutical sector as the research data of empirical analysis,the time is 2012-2018,using eviews10.0 software to carry out correlation analysis and regression analysis on relevant variables.Through the empirical study,this paper draws the following conclusions:(1)financial subsidies and tax preferences are positive incentives in terms of the impact on R &D investment;(2)tax incentives are better than financial subsidies on the positive incentives of R &D investment in technological innovation;(3)preferential corporate income tax is more likely to increase R &D investment than preferential turnover tax;the fifth chapter is policies Finally,based on the empirical results and policy status,this paper puts forward specific policy recommendations to promote R &D investment in biomedical industry from five aspects,including adjusting the current tax preferential policy positioning,increasing corporate income tax preferential efforts,supplementing and improving personal income tax,clarifying the fund use of R &D subsidies,and actively playing the incentive function of government subsidies.